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hair length and thickness. Thirdly, the
primary defect giving rise to Laron
syndrome is a block of growth hormone
signalling (Laron, 2002). Thus, some
abnormalities might be not owing
to IGF-I deficiency. As growth factors
share many intracellular signalling
pathways, a partial compensation of
such defects by IGF-I treatment might
be possible. Consequently, interpreta-
tion of data on Laron syndrome has to
be very cautious with respect to IGF-I’s
role in human hair follicles. Although
similarities regarding IGF-I and hair
production are apparent between man
and mouse, a detailed comparative
analysis is still missing.
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TO THE EDITOR
The erythrokeratodermas (EKs) include
a clinically and genetically heteroge-
neous group of disorders characterized
by erythematous and hyperkeratotic
lesions, either stationary or migratory.
Two major subtypes have been defined:
erythrokeratodermia variabilis (EKV,
OMIM 133200) and progressive sym-
metric erythrokeratodermia (PSEK,
OMIM 602036). PSEK is characterized
by fixed erythematous keratotic plaques
distributing symmetrically over the
body, particularly on the extremities,
the buttocks, and the faces, sometimes
together with palmoplantar keratoder-
ma. Two sisters have been described, in
which the younger one suffering EKV
whereas the older one suffering PSEK,
and this report brought forward the
hypothesis that PSEK and EKV were
different manifestations of a single
conditions (MacFarlane et al., 1991).
However, accumulating genetic studies
supported the distinct molecular
pathology underlying them (Richard
et al., 1998, 2002, 2003). The major
clinical feature distinguishing between
PSEK and EKV is the sharply outlined
geographical regions of migratory
erythema in the latter (Ishida-Yamamo-
to et al., 1997), and parakeratosis
is an evident pathological feature in
PSEK and usually not seen in
EKV. Furthermore, ichthyotic variant
of Vohwinkel syndrome, KID syn-
drome, and some transgradient forms
of palmoplantar keratoderma should
also be differentiated from PSEK based
on the clinical and histological char-
acteristics.
The pathologic mechanism of PSEK
is still unknown. No loci for PSEK have
been defined by genetic linkage anal-
ysis up to date. A frameshift mutation
(709insC) in the loricrin gene (OMIM
#152445) on chromosome 1q21 has
been identified in a Japanese PSEK
family with generalized, well-demar-
cated erythematous hyperkeratotic
plaques and mutilating palmoplantar
keratoderma (pseudoainhum) (Ishida-
Yamamoto et al., 1997). Loricrin is a
major structural component of the
crosslinked cell envelope of the epider-
mis, which participates in the formation
of keratohyalin granules (Hohl et al.,
1991; Candi et al., 1995), and the
responsibility of the loricrin gene for
variant form of Vohwinkel syndrome
has been demonstrated (Maestrini et al.,
1996). Some authors considered the
Japanese pedigree mentioned above
affecting variant form of Vohwinkel
syndrome rather than PSEK, because
pseudoainhum was usually not seen in
PSEK, and the location of above muta-
tion was only 21 bp upstream to that of
Vohwinkel syndrome variant form
(730insG) (Richard et al., 2002). Our
previous study has excluded the loricrin
gene is the responsibility gene for PSEK
(Cui et al., 2004).
To map the disease locus of PSEK,
we carried out a genome-wide scan in a
five-generation Chinese PSEK family
consisting of 27 individuals. There are
12 affected individuals in this family,
Abbreviations: EK, erythrokeratoderma; EKV, erythrokeratodermia variabilis; PSEK, progressive
symmetric erythrokeratodermia
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including five males and seven females.
Kindred examined exhibited the hall-
marks of autosomal dominant inheri-
tance with high penetrance. The pro-
band (IV:5) was a 16-year-old female,
her lesions developed when she was
3 years old and did not change much
thereafter. Physical examination shows
well-demarcated, slightly raised, hyper-
keratotic erythematous plaques distrib-
uted on the dorsum of hands and
feet symmetrically, accompany with
obviously palmoplantar keratoderma.
Clinical and histological features are
showed in Figure 1a–c. All patients
have typical features of the PSEK trait,
with normal mucous membranes, nails,
teeth, and hair. None patient shows
pseudoainhum.
This study was adherent to the
Declaration of Helsinki Principles and
approved by the medical ethical com-
mittee of the Anhui Medical University.
After obtaining informed consent,
18 members of this family (nine af-
fected and nine unaffected individuals)
participated in this genetic study by
donating 10 ml of blood for DNA
extraction and genotyping analysis.
Genomic DNAs were extracted from
peripheral blood by use of a blood kit
(Qiagen Inc., Hilden, Germany). We
first undertook a genome-wide scan
using 382 microsatellite markers from
the ABI’s Prism Linkage Mapping
Set (Version 2). All the markers
were genotyped in multiplex PCR
following the guidelines from the man-
ufacturer (Applied Biosystems, Foster
City, CA). The results of two-point
linkage analysis strongly suggest link-
age at 21q11.2–21q21.2 with LOD
scores of 2.82 at D21S1914 (y¼0.00).
We then selected 12 additional micro-
satellite markers from David Duffy’s
interpolated map (http://www2.qimr.
edu.au/davidD/), and the linkage results
from these added markers confirmed
our original finding by giving a max-
imum two-point LOD score of 4.33 at
marker D21S1257 (y¼0.00). All the
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Figure 1. Clinical features and haplotype analysis of this family. (a) Hyperkeratotic erythematous plaques on the dorsum of hands. (b) Hyperkeratotic
erythematous plaques on the dorsum of feet. (c) Histological results showing marked hyperkeratosis and parakeratosis (hematoxylin and eosin; bar¼ 1 mm).
(d) Haplotype analysis of this family: Black symbols denote affected individuals, while white symbols denote unaffected individuals. Haplotypes are shown
for all available members with marker names at the left of each generation. Black bars represent disease-carrying haplotypes, and the gray bar denotes
noninformative regions adjacent to critical recombination events. The black arrow indicates the proband of this family.
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two-point LOD scores of the 13 markers
analyzed in this study were summar-
ized in Table 1.
To determine the smallest interval
containing the PSEK locus, recombina-
tion events among the family members
were analyzed by haplotype recon-
struction (Figure 1d). Autosomal
dominant inheritance with 99.9% pe-
netrance was assumed. The affected
allele frequency was taken as 0.0001.
Marker allele frequencies were ob-
tained from all individuals’ genotyping
data. The recombination frequency was
assumed to be equal for both sexes.
Two-point linkage analysis was per-
formed using Linkage programs version
5.10, haplotypes were constructed with
Cyrillic Version 2.02 software. The
recombination events in individuals
III:4, III:6, IV:2, IV:3, IV:4, IV:5, IV:7,
and V:1 place the PSEK locus upper to
D21S1911 and an affected members
(IV:4) place the lower boundaries to
D21S1892. These results suggest that
the gene responsible for PSEK in this
family lies in the 19.02 cM interval
between D21S1911 and D21S1892.
This interval spans about 9 Mb on the
physical map. There are 23 genes within
the critical regions, including 18 con-
firmed genes. Four known genes (NRIP1
(OMIM 602490), USP25 (OMIM604736),
BTG3 (OMIM 605674), and CHODL
(OMIM 607247)), whose transcripts had
been isolated from skin cDNA libraries
could be selected as candidate genes
for further investigation. Ubiquitin,
the encoded protein of USP25, is a highly
conserved 76-amino-acid protein in-
volved in the regulation of intracellular
protein breakdown, cell cycle regulation,
and stress response. BTG3 is a novel
member of the PC3/BTG/TOB family
of growth inhibitory genes. CHODL
is a type I transmembrane protein
homologous to C-type lectins, which
characterized by calcium-dependent
carbohydrate-binding activity and a
common carbohydrate recognition do-
main. Keratin genes were considered to
be good candidates because several
hyperkeratotic cutaneous disorders are
caused by mutations of keratins (Fuchs
and Cleveland, 1998; Coulombe and
Omary, 2002), but no known keratin
gene was found in this locus.
In conclusion, we identified a novel
locus for PSEK on chromosome
21q11.2–21q21.2 in a Chinese family.
It will aid future identification of the
responsible gene, which will be useful
for the understanding of the molecular
mechanism of PSEK.
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TO THE EDITOR
Staphylococcal scalded skin syndrome
(SSSS) is a generalized blistering skin
disease caused by Staphylococcus aur-
eus producing exfoliative toxin (ET). ET
is a serine protease that specifically
digests desmoglein 1 (Dsg1), the auto-
immune target for pemphigus foliaceus
(PF). Out of 30 patients with SSSS, six
(20.0%) patients developed low titers of
anti-Dsg1 IgG, but no detectable anti-
Dsg3 IgG, 7 days or more after the
onset of the disease. Although other
genetic or environmental factors are
necessary for the full development of
pemphigus, this finding provides evi-
dence that infection could trigger the
autoimmune reaction.
A major question in understanding
the pathophysiology of autoimmune
disease is what triggers the immune
response. One postulated mechanism,
molecular mimicry, has been that
infectious agents might cause anti-
bodies that bind self-antigens, a good exa-
mple being streptococcal antigens in
rheumatic heart disease (Wucherpfennig,
2001). In such cases, the antibodies that
are produced against the infectious
agent are thought to coincidentally
crossreact with normal tissues. The
recent elucidation of the pathophysiol-
ogy of an antibody-mediated tissue-
specific autoimmune disease, PF, and
two related infectious diseases, bullous
impetigo (BI) and SSSS, all of which
target the same molecule, Dsg1, sug-
gested to us another mechanism by
which an infectious agent could trigger
an autoimmune response. In this
mechanism, we hypothesize that a
bacterial toxin could bind to and
partially degrade a self-antigen, with
the modified self-antigen triggering the
immune response.
Impetigo is the most common bac-
terial infection of children and 30% of
these patients have BI, which is caused
by S. aureus that produces ETs. SSSS is a
generalized form of BI, which occurs in
newborns, young children, and adults
with renal failure and/or who are
immunocompromised. In the early
1970s, ETs of two major serotypes,
ETA and ETB, were shown to produce
blisters in the superficial epidermis
when passively transferred to neonatal
mice (Melish and Glasgow, 1970). It
took almost 30 years to elucidate the
pathophysiological mechanism of ac-
tion of ETs, which have recently been
shown to be glutamate-specific serine
proteases that specifically bind and
cleave Dsg1 (Amagai et al., 2000).
Desmogleins are cadherin-type cell–-
cell adhesion molecules found in des-
mosomes and play a critical role in
maintaining tissue integrity in epithelial
and other tissues (Green and Gaudry,
2000).
Desmogleins are also affected in the
skin autoimmune blistering disease,
pemphigus (Payne et al., 2004). Among
four isoforms of desmoglein, Dsg1 is
targeted by IgG autoantibodies in PF,
which shows superficial epidermal blis-
ters with identical histological findings
to SSSS/BI. Thus, in both PF and SSSS/BI
the inactivation of Dsg1 causes super-
ficial blisters in skin.
If, as postulated above, altered anti-
gen, in this case Dsg1, could trigger an
immune response, we would expect
that some patients with SSSS or BI
produce at least low-level antibodies
against Dsg1. To address this hypo-
thesis, we examined a total of 58 serum
samples from 30 patients with SSSS
and 12 serum samples from 12 patients
with BI after informed consent with
Abbreviations: BI, bullous impetigo; Dsg1, desmoglein 1; ET, exfoliative toxin; PF, pemphigus foliaceus;
SSSS, staphylococcal scalded skin syndrome
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